REGENXBIO to Host Investor Event Highlighting Surabgene Lomparvovec (Sura-vec) in Wet AMD on October 20
REGENXBIO will host an investor event on October 20, 2026 at 1:00 p.m. ET to review the surabgene lomparvovec (sura-vec) clinical program in wet age-related macular degeneration. The event will feature management and five retina specialists discussing the ATMOSPHERE and ASCEND pivotal trials and commercial readiness ahead of topline pivotal data anticipated in 4Q 2026.
Key figures
- Drug Name
- surabgene lomparvovec (sura-vec, ABBV-RGX-314)
- Phase Of Trial
- pivotal (ATMOSPHERE and ASCENT)
- Event Date
- October 20, 2026, 1:00 p.m. ET
- Data Readout Timing
- 4Q 2026
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.